.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,346,532

« Back to Dashboard

Claims for Patent: 6,346,532

Title: Amide derivatives or salts thereof
Abstract:##STR1## Amide derivatives represented by general formula (I) or salts thereof wherein each symbol has the following meaning: ring B: an optionally substituted heteroaryl optionally fused with a benzene ring; X: a bond, lower alkylene or lower alkenylene optionally substituted by hydroxy or lower alkyl, carbonyl, or a group represented by --NH-- (when X is lower alkylene optionally substituted by lower alkyl which may be bonded to the hydrogen atom bonded to a constituent carbon atom of ring B to form lower alkylene to thereby form a ring); A: a lower alkylene or a group represented by -(lower alkylene)--O--; R.sup.1a and R.sup.1b : the same or different and each hydrogen or lower alkyl; R.sup.2 : hydrogen or halogeno; and Z: nitrogen or a group represented by .dbd.CH--. The compounds are useful as a diabetes remedy which not only functions to both accelerate the secretion of insulin and enhance insulin sensitivity but has an antiobestic action and an antihyperlipemic action based on its selective stimulative action on a .beta..sub.3 receptor.
Inventor(s): Maruyama; Tatsuya (Tsukuba, JP), Suzuki; Takayuki (Tsukuba, JP), Onda; Kenichi (Tsukuba, JP), Hayakawa; Masahiko (Tsukuba, JP), Moritomo; Hiroyuki (Tsukuba, JP), Kimizuka; Tetsuya (Tsukuba, JP), Matsui; Tetsuo (Tsukuba, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/529,096
Patent Claims: 1. A compound of formula (I): ##STR44##

in the formula, each of the symbols means as follows:

ring B is a heteroaryl group which is unsubstituted or substituted and is optionally fused with a benzene ring;

X is a bond, or a lower alkylene or an alkenylene, both of which are unsubstituted or substituted with hydroxy or a lower alkyl group, or X is a carbonyl or a group represented by --NH--, and when X is a lower alkylene which is substituted with a lower alkyl group, a carbon atom of the ring B optionally bonds with the lower alkyl group so that a ring is formed;

A is a lower alkylene or a group represented by -lower alkylene-O--;

R.sup.1a, R.sup.1b are the same or different and each is a hydrogen atom or a lower alkyl group;

R.sup.2 is a hydrogen atom or a halogen atom; and

Z is a group represented by .dbd.CH--; or a salt thereof.

2. The compound of formula (I) or the salt thereof according to claim 1, wherein A is methylene, ethylene, or a group represented by --CH.sub.2 O--.

3. The compound of formula (I) or the salt thereof according to claim 2, wherein the ring B is a heteroaryl group which is substituted with a substituent chosen from a halogen atom, lower alkyl, lower alkenyl, lower alkynyl, hydroxy, sulfanyl, halogeno lower alkyl, lower alkyl-O--, lower alkyl-S--, lower alkyl-O--CO--, carboxy, sulfonyl, sulfinyl, lower alkyl-SO--, lower alkyl-SO.sub.2 --, lower alkyl-CO--, lower alkyl-CO--O--, carbamoyl, lower alkyl-NH--CO--, di-lower alkyl-N--CO--, nitro, cyano, amino, lower alkyl-NH--, di-lower alkyl-N--, aryl-lower alkyl, halogeno aryl-lower alkyl, guanidino, lower alkyl-CO--NH, and lower alkyl-SO.sub.2 --NH--.

4. The compound of formula (I) or the salt thereof according to claim 3, wherein R.sup.2, R.sup.1a and R.sup.1b are each a hydrogen atom, and Z is .dbd.CH--.

5. A compound of formula (Ia): ##STR45##

in the formula, each of the symbols means as follows:

ring B is a heteroaryl group;

X is a bond or a lower alkylene group;

R is a hydrogen atom, a halogen atom, a lower alkyl group, amino group, an aryl lower alkyl group, or a halogeno aryl-lower alkyl group; or a salt thereof.

6. A compound:

(R)-4'-[2-[(2-Hydroxy-2-phenylethyl)amino]ethyl]-2-pyridinecarboxyanilide,

(R)-2-[1-(4-chlorobenzyl)-1H-imidazol-2-yl)-4'-[2-[(2-hydroxy-2-phenylethyl )amino]ethyl]-acetanilide, (R)-2-[1-(3,4-dichlorobenzyl)-1H-tetrazol-5-yl]-4'-[2-[(2-hydroxy-2-phenyl ethyl)amino]ethyl]acetanilide,

(R)-2-(2-aminothiazol-4-yl)-4'-[2-(2-hydroxy-2-phenylethyl)amino]ethyl]acet anilide,

(R)-2-(2-benzyl-1H-1,2,4-triazol-3-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)-ami no]ethyl]acetanilide,

(R)-2-(2-aminopyridin-6-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]ace tanilide, (R)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-2-(2-pyridyl)acetanilide,

(R)-4'-[2-[(2-hydroxy-2-phenylethyl)-amino]ethyl)-2-(2-pyrazinyl)acetanilid e, (R)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl)-2-(2-pyrimidinyl)-acetani lide, or a salt of any of the foregoing.

7. A composition comprising at least one compound of formula (I) or the salt thereof as claimed in one of claims 1 through 4 in a pharmaceutically acceptable carrier.

8. The composition as claimed in claim 7, wherein the at least one compound of formula (I) or the salt thereof is present in an amount effective for the treating of diabetes mellitus in a human or animal patient in need of such treating.

9. The compound of formula (I) as claimed in claim 1, wherein the compound of formula (I) is an optical isomer, a hydrate, or a solvate of the compound of formula (I).

10. A composition comprising a compound of formula (I) as claimed in claim 1 in a pharmaceutically acceptable carrier, wherein the compound of formula (I) is present as a polymorphic substance.

11. A composition comprising at least one compound of formula (I) or the salt thereof as claimed in claim 5, in a pharmaceutically acceptable carrier.

12. A composition comprising at least one compound or the salt of any of the foregoing as claimed in claim 6, in a pharmaceutically acceptable carrier.

13. A method for treating diabetes mellitus in a human or animal patient in need of such treatment comprising administering to the patient an amount of a compound of formula (I) as claimed in claim 1, wherein the amount is an amount effective for such treatment.

14. A method for treating obesity in a human or animal patient in need of such treatment comprising administering to the patient an amount of a compound of formula (I) as claimed in claim 1, wherein the amount is an amount effective for such treatment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc